Amgen and Sanofi Drugs Can Reach U.S. Without Long Studies

U.S. regulators won’t require Amgen Inc., Sanofi, Pfizer Inc. and other companies developing the next class of cardiovascular medicines to prove the therapies prevent heart attacks and death before they’re approved.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.